Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover key insights every first time investor should know. Equip yourself with the knowledge for a successful and rewarding investing experience.
28,352 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Micron Technology is at a pivotal moment as AI-related demand collides with a cyclical memory market. Shares have sur...
Qualcomm surged in early trading after landing Meta Platforms as a data center customer for its Dragonfly chip, then ...
As Verizon nears its July 24 earnings, investors are eyeing a potential near-25% upside driven by steady cash flow, a...
AI misinfo is not just a tech issue—it's a real-world risk that can touch markets, portfolios, and lives. This articl...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
Citi warns that the stock market frothiest since the global financial crisis has created vulnerabilities, but says pa...
A top chip maker delivered a surprising quarterly beat, reviving investor appetite and igniting a debate over AI memo...
As Boyd Gaming nears its July 23 earnings, traders are weighing a potential 17.2% upside fueled by a disciplined buyb...
SpaceX is lining up a blockbuster IPO that could outpace the entire 2025 IPO slate. Analysts estimate a multi-billion...
Intel has surged 116% in the past month as AI demand strengthens data-center demand and early talks of a potential Ap...
Lucid stock deeply oversold scenarios meet a potential production ramp and strategic partnerships that could unlock m...